AMP-activated protein kinase: a potential therapeutic target for triple-negative breast cancer.

Breast Cancer Research : BCR
Wei CaoYong Wu

Abstract

Triple-negative breast cancer (TNBC) is an aggressive subset of breast carcinomas that lack expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2). Unlike other breast cancer subtypes, targeted therapy is presently unavailable for patients with TNBC. In spite of initial responses to chemotherapy, drug resistance tends to develop rapidly and the prognosis of metastatic TNBC is poor. Hence, there is an urgent need for novel-targeted treatment methods or development of safe and effective alternatives with recognized mechanism(s) of action. AMP-activated protein kinase (AMPK), an energy sensor, can regulate protein and lipid metabolism responding to alterations in energy supply. In the past 10 years, interest in AMPK has increased widely since it appeared as an attractive targeting molecule for cancer therapy. There has been a deep understanding of the possible role of abnormal AMPK signaling pathways in the regulation of growth and survival and the development of drug resistance in TNBC. The increasing popularity of using AMPK regulators for TNBC-targeted therapy is supported by a considerable development in ascertaining the molecular pathways implicated. This review h...Continue Reading

References

Nov 21, 2002·Biochemical Society Transactions·D G Hardie, D A Pan
Feb 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·Reuben J ShawLewis C Cantley
Apr 26, 2005·BMJ : British Medical Journal·Josie M M EvansAndrew D Morris
Sep 23, 2006·Developmental Biology·Baohong ZhangTodd A Anderson
Aug 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rebecca DentSteven A Narod
Feb 6, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cornelia LiedtkeLajos Pusztai
Mar 5, 2008·Cancer Research·Devanand SarkarPaul B Fisher
Jul 5, 2008·Cell Death and Differentiation·F ScarlattiP Codogno
Jan 16, 2009·Breast Cancer Research : BCR·David VaughtJin Chen
Feb 18, 2009·The Journal of Clinical Investigation·Byoung Kwon YooDevanand Sarkar
Jul 25, 2009·Nature Reviews. Cancer·David B Shackelford, Reuben J Shaw
Sep 3, 2009·BMC Cancer·Sirwan M HadadAlastair M Thompson
Sep 26, 2009·Biochimica Et Biophysica Acta·S Fogarty, D G Hardie
Nov 27, 2009·Proceedings of the National Academy of Sciences of the United States of America·Luni EmdadPaul B Fisher
Jun 17, 2010·British Journal of Cancer·S KashiwagiK Hirakawa
Sep 10, 2010·Cold Spring Harbor Perspectives in Biology·Michael W Harr, Clark W Distelhorst
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Sep 6, 2011·Nature Cell Biology·Maria M Mihaylova, Reuben J Shaw
Mar 1, 2012·Critical Reviews in Food Science and Nutrition·Jia XuXiang-Hua Yan
Apr 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gunter von MinckwitzSibylle Loibl
Apr 27, 2012·Nature Reviews. Cancer·Eileen White
Jan 16, 2013·Proceedings of the National Academy of Sciences of the United States of America·Daniela A FerraroYosef Yarden
May 7, 2013·Cancer Research·Jiyong Liang, Gordon B Mills
Aug 21, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hiroko MasudaNaoto T Ueno
Nov 23, 2013·Cancer Letters·Xiangling FengYaguang Xi
Jul 16, 2014·Apoptosis : an International Journal on Programmed Cell Death·L L FuB Liu
Jan 6, 2015·BMJ : British Medical Journal·Konstantinos K TsilidisJohn P A Ioannidis
Feb 27, 2015·Breast Cancer Research and Treatment·C Villarreal-GarzaS A Narod

❮ Previous
Next ❯

Citations

Jul 31, 2019·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Z WuJ Jin
Aug 15, 2019·BMC Complementary and Alternative Medicine·Yu-Te LiuTsai-Ching Hsu
Oct 20, 2020·Frontiers of Medicine·Deyu ZhangQinong Ye
Dec 17, 2020·Journal of Biochemical and Molecular Toxicology·Gamze Guney EskilerMurat Kasap
Sep 17, 2020·European Journal of Medicinal Chemistry·Rajibul Islam, Kok Wai Lam
May 25, 2021·World Journal of Methodology·Cornelius J FernandezJoseph M Pappachan
Jan 30, 2021·The European Respiratory Journal·Yan Hui GiamJames D Chalmers

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft

Software Mentioned

Prozac

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.